In Vitro Design of Preclinical Models for Chemotherapy Combinations in Human Breast Tumours

Journal Title: Journal of Clinical and Diagnostic Research - Year 2019, Vol 13, Issue 5

Abstract

ABSTRACT Introduction: Globally, breast cancer persists a main cause of mortality. Because the number of possible drug combinations is basically unlimited, a strategy for the design of combination chemotherapy regimen of two anti-breast cancer drugs and determining the most promising combinations is crucial for improving the therapeutic outcomes and overcome the multi-therapeutic approach and holds the promise of delivering therapy to those in need. Aim: To assess the activity of combination of Doxorubicin and 5-fluorouracil on Human Breast Cancer Cell line (MCF-7). Materials and Methods: The cytotoxicity of Doxorubicin (DOX) and 5 fluorouracil (5FU) drugs or their combinations were evaluated by using 3-(4,5-Dimethylthiazol-2-yl)-2, 5 Diphenyltetrazolium Bromide (MTT) viability assay against human breast cancer cell line MCF-7. Then, the combination effect proposed by Chou TC et al., based on IC50 values obtained from drugs alone and their combination was evaluated by Combination Index (CI) to determine the nature of synergism, antagonism and additivity action of drug combinations as: synergistic effect is recorded if CI <1, additive effect if CI=1, or antagonism if CI >1, the median-effect dose (Dm) also studied. Dose-Reduction Index (DRI) was also calculated to indicate the level of dose reduction for each drug in synergistic combination. Experiments were achieved with triplicate samples. The MTT assay data were expressed as mean±Standard Deviation (SD). The IC50 values for each drug were computed by GraphPad Prism 5.2 software (GraphPad Software Inc., USA). Dose-effect curve parameters, CI values, Fa-CI, DRI-Faplot were calculated by CompuSyn program. Results: The proliferation of MCF-7 cells was inhibited by 5 FU and DOX anti-cancer drugs in a dose-dependent effect. The DOX at (0.1) nM was antagonistic according to CI value which was 2.82283, while at (1) nM, the CI was 0.39429 that indicate strong synergistic action. Conclusion: This study confirmed the favourable effect of 5 FU in combination with DOX for treatment of breast cancer cell MCF-7 better than the single drug treatment.

Authors and Affiliations

Randa Mohammed Dhahi

Keywords

Related Articles

Effect of Environmental Intervention on the Consumption of Rice without Toxic Metals Based on the Health Belief Model and Ecological-Social Model

Introduction: The effect of instructional models on the changing behaviour of consuming contaminated rice with toxic metals has not been investigated in Iran yet. Aim: To compare effect of Health Belief Model (HBM) and E...

Cytological Diagnosis of an Uncommon High Grade Malignant Thyroid Tumour: A Case Report

Anaplastic Thyroid Carcinoma (ATC) is a relatively uncommon highly malignant tumour originating from the follicular cells of thyroid gland having poor prognosis. It accounts for 2% to 5% of all thyroid carcinomas and pat...

Palmer Freckling as a New Clinical Marker: Clinico-epidemiological Study of 26 Cases of Neurofibromatosis Type-1

ABSTRACT Introduction: Neurofibromatosis Type 1 (NF-1) is an autosomal dominant genodermatosis characterised by Café Au lait Macules (CALMs), multiple neurofibromas, iris Lisch nodules, axillary and inguinal freckling an...

Therapy Related Acute Promyelocytic Leukaemia (APML) in a Breast Cancer Survivor: Another Tale of an Ally Turned Adversary

ABSTRACT With an increase in the use of high dose chemotherapeutic regimens, higher cure rates and longer survival periods of cancer patients, the incidence of secondary malignancies are increasing. Therapy related Myelo...

Irritable Bowel Syndrome and Bronchial Asthma: Are They Associated in Indian Population?

Introduction: Irritable Bowel Syndrome (IBS), a common gastrointestinal (GI) disorder has been linked with asthma implying a clue to its pathophysiology as being some form of allergic response. Previous studies from othe...

Download PDF file
  • EP ID EP585866
  • DOI 10.7860/JCDR/2019/40273.12859
  • Views 94
  • Downloads 0

How To Cite

Randa Mohammed Dhahi (2019). In Vitro Design of Preclinical Models for Chemotherapy Combinations in Human Breast Tumours. Journal of Clinical and Diagnostic Research, 13(5), 5-5. https://europub.co.uk/articles/-A-585866